Intra-Cellular Therapies
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch ITCI and buy or sell other stocks, ETFs, and their options commission-free!About ITCI
Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system.
CEOSharon L. Mates, PhD
CEOSharon L. Mates, PhD
Employees860
Employees860
HeadquartersBedminster, New Jersey
HeadquartersBedminster, New Jersey
Founded2002
Founded2002
Employees860
Employees860
ITCI Key Statistics
Market cap14.01B
Market cap14.01B
Price-Earnings ratio-182.70
Price-Earnings ratio-182.70
Dividend yield—
Dividend yield—
Average volume1.90M
Average volume1.90M
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$131.98
52 Week high$131.98
52 Week low$64.09
52 Week low$64.09
Stock Snapshot
As of today, Intra-Cellular Therapies(ITCI) shares are valued at $131.87. The company's market cap stands at 14.01B, with a P/E ratio of -182.70.
On 2026-01-14, Intra-Cellular Therapies(ITCI) shares started trading at —, with intraday highs of — and lows of —.
Trading volume for Intra-Cellular Therapies(ITCI) stock has reached 0, versus its average volume of 1.9M.
The stock's 52-week range extends from a low of $64.09 to a high of $131.98.
The stock's 52-week range extends from a low of $64.09 to a high of $131.98.
People also own
Based on the portfolios of people who own ITCI. This list is generated using Robinhood data, and it’s not a recommendation.